ADIL I. DAUD
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 135
- Cancer Immunotherapy and Biomarkers 72
- CAR-T cell therapy research 52
- Cutaneous Melanoma Detection and Management 26
- Immunology 55
- Immunotherapy and Immune Responses 35
- Immune Cell Function and Interaction 13
- Co-authors
- Pamela N. Münster (26 shared papers)Omid Hamid (24 shared papers)Caroline Robert (17 shared papers)Antoni Ribas (19 shared papers)Daniel M. Sullivan (13 shared papers)Katy K. Tsai (18 shared papers)Nageatte Ibrahim (8 shared papers)Alain Patrick Algazi (24 shared papers)
- Journals
- Journal of Clinical Oncology (20 papers)Annals of Oncology (19 papers)Clinical Cancer Research (18 papers)European Journal of Cancer (13 papers)Journal for ImmunoTherapy of Cancer (8 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
ADIL I. DAUD
233 papers receiving 37.5k citations
ADIL I. DAUD's Hit Papers
Peers
Comparison fields: 5 of 151
- Oncology 23.9k
- Immunology 11.8k
- Molecular Biology 12.2k
- Cancer Research 2.3k
- Biotechnology 1.1k
Countries citing papers authored by ADIL I. DAUD
This map shows the geographic impact of ADIL I. DAUD's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by ADIL I. DAUD with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites ADIL I. DAUD more than expected).
Fields of papers citing papers by ADIL I. DAUD
This network shows the impact of papers produced by ADIL I. DAUD. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by ADIL I. DAUD. The network helps show where ADIL I. DAUD may publish in the future.
Co-authors
The 25 scholars most cited alongside ADIL I. DAUD, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 240 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2015 | 4893 |
| 2 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2928 |
| 3 | Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Hit paper breakdown → | 2012 | 2337 |
| 4 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1540 |
| 5 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Hit paper breakdown → | 2015 | 1348 |
| 6 | PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Hit paper breakdown → | 2016 | 1030 |
| 7 | Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity Hit paper breakdown → | 2014 | 1013 |
| 8 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 1007 |
| 9 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 937 |
| 10 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Hit paper breakdown → | 2016 | 905 |
| 11 | A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments Hit paper breakdown → | 2018 | 816 |
| 12 | Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 Hit paper breakdown → | 2018 | 790 |
| 13 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 742 |
| 14 | Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Hit paper breakdown → | 2015 | 672 |
| 15 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab Hit paper breakdown → | 2016 | 605 |
| 16 | Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Hit paper breakdown → | 2008 | 589 |
| 17 | Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma Hit paper breakdown → | 2016 | 550 |
| 18 | Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity Hit paper breakdown → | 2019 | 510 |
| 19 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Hit paper breakdown → | 2017 | 469 |
| 20 | Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Hit paper breakdown → | 2009 | 465 |
About ADIL I. DAUD
ADIL I. DAUD is a scholar working on Oncology, Immunology, Molecular Biology, Biotechnology and Cancer Research, having authored 240 papers that have together received 38.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (72 papers), CAR-T cell therapy research (52 papers), Melanoma and MAPK Pathways (49 papers), Immunotherapy and Immune Responses (35 papers), Cutaneous Melanoma Detection and Management (26 papers), Immune Cell Function and Interaction (13 papers), Microbial Inactivation Methods (10 papers) and Histone Deacetylase Inhibitors Research (9 papers). The work is most often cited by research in Oncology (23.9k citations), Immunology (11.8k citations), Molecular Biology (12.2k citations), Cancer Research (2.3k citations) and Biotechnology (1.1k citations). ADIL I. DAUD has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Pamela N. Münster, Omid Hamid, Caroline Robert, Antoni Ribas, Daniel M. Sullivan, Katy K. Tsai, Nageatte Ibrahim, Alain Patrick Algazi, Douglas C. Marchion and Matthew F. Krummel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, European Journal of Cancer and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.